-
Functional Areas
- Principal Recipient Start-Up
-
Legal Framework
- Overview
- Project Document
-
The Grant Agreement
- UNDP-Global Fund Grant Regulations
- Grant Confirmation
- Grant Confirmation: Face Sheet
- Grant Confirmation: Conditions
- Grant Confirmation: Conditions Precedent (CP)
- Grant Confirmation: Special Conditions (SCs)
- Grant Confirmation: Schedule 1, Integrated Grant Description
- Grant Confirmation: Schedule 1, Performance Framework
- Grant Confirmation: Schedule 1, Summary Budget
- Implementation Letters and Performance Letters
- Agreements with Sub-recipients
- Agreements with Sub-sub-recipients
- Signing Legal Agreements and Requests for Disbursement
- Language of the Grant Agreement and other Legal Instruments
- Amending Legal Agreements
- Other Legal and Implementation Considerations
- Legal Framework for Other UNDP Support Roles
-
Health Product Management
- Overview - Health Product Management
- UNDP Quality Assurance Policy
- Product Selection
- Quantification and Forecasting
- Supply Planning of Health Products
-
Sourcing and regulatory aspects
- Global Health Procurement Center (GHPC)
- Development of List of Health Products
- Development of the Health Procurement Action Plan (HPAP)
- Health Procurement Architecture
- Local Procurement of health products
- Procurement of Pharmaceutical Products
- Procurement of non-pharmaceutical Health Products
- Other Elements of the UNDP Procurement Architecture
- Submission of GHPC CO Procurement Request Form
- Guidance on donations of health products
- International freight, transit requirements and use of INCOTERMS
- Inspection and Receipt
- Storage
- Inventory Management
- Distribution
- Quality monitoring of health products
- Waste management
- Rational use
- Pharmacovigilance
- Risk Management for PSM of health products
- Compliance with the Global Fund requirements
- UNDP Health PSM Roster
-
Financial Management
- Overview
- Grant-Making and Signing
- Grant Implementation
- Sub-recipient Management
- Grant Reporting
- Grant Closure
- CCM Funding
- Import duties and VAT / sales tax
-
Monitoring and Evaluation
- Overview
- Differentiation Approach
- Monitoring and Evaluation Components of Funding Request
- Monitoring and Evaluation Components of Grant Making
- M&E Components of Grant Implementation
- Sub-Recipient Management
- Grant Reporting
-
Capacity development and transition, strengthening systems for health
- Overview
- Interim Principal Recipient of Global Fund Grants
- A Strategic Approach to Capacity Development
- Resilience and Sustainability
- Legal and Policy Enabling Environment
- Functional Capacities
- Capacity Development and Transition
- Transition
- Capacity Development Objectives and Transition Milestones
- Capacity Development Results - Evidence From Country Experiences
- Capacity development and Transition Planning Process
- Capacity Development and Transition - Lessons Learned
-
Risk Management
- Overview
- Introduction to Risk Management
-
Risk Management in the Global Fund
- Global Fund Risk Management Framework
- Local Fund Agent
- Challenging Operating Environment (COE) Policy
- Additional Safeguard Policy
- Global Fund Risk Management Requirements for PRs
- Global Fund Risk Management Requirements During Funding Request
- Global Fund Review of Risk Management During Grant Implementation
- Risk management in UNDP
- Risk Management in UNDP-managed Global Fund projects
- UNDP Risk Management Process
- Risk management in crisis settings
- Audit and Investigations
- Human rights, key populations and gender
- Human resources
-
Grant closure
- Overview
- Terminology and Scenarios for Grant Closure Process
-
Steps of Grant Closure Process
- 1. Global Fund Notification Letter 'Guidance on Grant Closure'
- 2. Preparation and Submission of Grant Close-Out Plan and Budget
- 3. Global Fund Approval of Grant Close-Out Plan
- 4. Implementation of Close-Out Plan and Completion of Final Global Fund Requirements (Grant Closure Period)
- 5. Operational Closure of Project
- 6. Financial Closure of Project
- 7. Documentation of Grant Closure with Global Fund Grant Closure Letter
Quality Control (QC) activities
As per the UNDP QA Policy, products purchased through UNDP must be tested according to a randomized sampling plan, which is based on a risk assessment by product category and by product. The GHPC QAS Team has issued guidance for Country Offices outlining 1) how to prepare a multi-year QC Plan including a template, and 2) how to prepare an annual Sampling Plan including a template and a calculation tool and instructions on how to use the tool.
The annual sampling plan should include the number of batches to be tested based on the annual procurement plan. Both random and targeted risk-based sampling is recommended at different points across the supply chain. The selection of batches to be tested should follow the recommendations in section VII of the Guidance for UNDP Country Offices on Health Products Quality Assurance in the Supply Chain.
The PR must implement the annual plan and must maintain a record of the test results. The test results must also be shared with the GHPC QAS team.
For FPPs and Diagnostics approved by the WHO ERP and procured with Global Fund grant resources, the Global Fund Secretariat is responsible for organizing and paying for the quality control of these products prior to their shipment. UNDP COs are responsible for notifying the Global Fund Secretariat of their intent to purchase such products – using the following forms pharmaceuticals, additional Order of ERP Pharmaceutical Products, and diagnostics – and must receive a “no objection letter” (NOL) before confirming the purchase order. The NOL must be provided to the GHPC HPS and QAS teams before the PO can be issued.
Once the products are ready for sampling, the manufacturer informs the Global Fund who organizes the sampling and testing by a third-party laboratory contracted by the Global Fund. Upon receipt of a successful test results, the Global Fund will issue the final letter, including the test report, to the PR and the manufacturer, authorizing the product shipment. This letter must also be provided to the GHPC QAS team for their records.
For pharmaceuticals, other than ERP products, UNDP has established LTAs with Quality Control laboratories that are WHO prequalified for the provision of sampling and testing of pharmaceuticals. The existing LTAs expired at the end of 2023 and are being re-tendered. A link to the new LTAs and corresponding standard operating procedures (SOPs) will be shared later in 2024. LTAs for pre-shipment inspection and for QC laboratories for sampling and testing of other product categories are being established and should be available during semester 2 of 2024.
Additional guidance to support this area of work are also available through resources listed below: